Inherited variations in the SOD and GPX gene families and cancer risk

Free Radical Research

Volumn 46, Issue 5, 2012, Pages 581-599

  Yuzhalin, Arseniy E ^a   Kutikhin, Anton G ^b  

^a KEMEROVO STATE UNIVERSITY   (Russian Federation)

^b KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

DNA damage; Oxidative stress; single nucleotide polymorphism; SNP

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME P450 1B1; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; ISOENZYME; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL ENZYME; MYELOPEROXIDASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SELENIUM; SUPEROXIDE DISMUTASE; XRCC1 PROTEIN;

3' UNTRANSLATED REGION; ACOUSTIC NEURINOMA; ALCOHOLISM; BLADDER CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE REGULATION; CIGARETTE SMOKING; COLORECTAL CARCINOMA; DNA DAMAGE; ENZYME ACTIVITY; ESOPHAGUS CARCINOMA; GENE OVEREXPRESSION; GENE REPLICATION; GENETIC DAMAGE; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; GLIOBLASTOMA; HELICOBACTER INFECTION; HETEROZYGOSITY LOSS; HUMAN; INHERITANCE; INTESTINE METAPLASIA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG CARCINOMA; MALIGNANT TRANSFORMATION; MEDICAL RESEARCH; MENINGIOMA; META ANALYSIS (TOPIC); MULTIGENE FAMILY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PREDICTIVE VALUE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMACH CARCINOMA; THYROID CANCER; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER;

CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE PEROXIDASE; HUMANS; NEOPLASMS; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; REACTIVE OXYGEN SPECIES; RISK; SUPEROXIDE DISMUTASE;

EID: 84859015761     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2012.658515     Document Type: Review

References (127)

1. Florian M. The nature and mechanism of superoxide production by the electron transport chain: Its relevance to agin. Age 2000;23:227-253.
2. Stadtman ER. Protein oxidation and aging. Science 1992; 257:1220-1224.
3. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005;10:1881-1896.
4. Caporaso N. The molecular epidemiology of oxidative damage to DNA and cancer. J Natl Cancer Inst 2003;95: 1263-1265.
5. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1-40.
6. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000;21:361-370.
7. Jackson JH. Potential molecular mechanisms of oxidant-induced carcinogenesis. Environ Health Perspect 1994;102 Suppl 10:155-157.
8. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F, et al. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003;13:145-157.
9. Wang M, Dhingra K, Hittelman WN, Liehr JG, de Andrade M, Li D, et al. Lipid peroxidation-induced putative malondialdehyde-DNA adducts in human breast tissues. Cancer Epidemiol Biomarkers Prev 1996;5:705-710.
10. Boyd NF, McGuire V. The possible role of lipid peroxidation in breast cancer risk. Free Radic Biol Med 1991;10: 185-190.
11. Ames BN. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 1983;23;221: 1256-1264.
12. Rohan TE, Hiller JE, McMichael AJ. Dietary factors and survival from breast cancer. Nutr Cancer 1993;20:167-177.
13. Millikan RC, Player J, de Cotret AR, Moorman P, Pittman G, Vannappagari V, et al. Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites. Breast Cancer Res 2004;6:R264-274.
14. Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA, Hunter DJ. Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:989-996.
15. Cai Q, Shu XO, Wen W, Cheng JR, Dai Q, Gao YT, et al. Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Breast Cancer Res 2004;6:R647-R655.
16. Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 1999;59: 602-606.
17. Mitrunen K, Sillanpä ä P, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 2001;22:827-829.
18. Bica CG, da Cruz IB, de Moura da Silva LL, Toscani NV, Zettler CG, Graudenz MS, et al. Association of manganese superoxide dismutase gene polymorphism (Ala-9Val) and breast cancer in males and females. J Bras Patol Med Lab 2007;43:219-225.
19. Slanger TE, Chang-Claude J, Wang-Gohrke S. Manganese superoxide dismutase Ala-9Val polymorphism, environmental modifi ers, and risk of breast cancer in a German population. Cancer Causes Control 2006;17:1025-1031.
20. Cox DG, Tamimi RM, Hunter DJ. Gene x Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control study. BMC Cancer 2006;6:217.
21. Kocabaş NA, Sarda ş S, Cholerton S, Daly AK, Elhan AH, Karakaya AE, et al. Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility. Cell Biochem Funct 2005;23:73-76.
22. Bergman M, Ahnström M, Palmebäck Wegman P, Wingren S. Polymorphism in the manganese superoxide dismutase (MnSOD) gene and risk of breast cancer in young women. J Cancer Res Clin Oncol 2005;131:439-444.
23. Kim MK, Ahn SH, Son BH, Sung MK. Plasma antioxidant concentration, not superoxide dismutase polymorphism, is associated with breast cancer risk in Korean women. Nutr Res 2010;30:705-713.
24. Egan KM, Thompson PA, Titus-Ernstoff L, Moore JH, Ambrosone CB. MnSOD polymorphism and breast cancer in a population-based case-control study. Cancer Lett 2003;199:27-33.
25. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, et al. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 2008;108:137-149.
26. Gaudet MM, Gammon MD, Santella RM, Britton JA, Teitelbaum SL, Eng SM, et al. MnSOD Val-9Ala genotype, proand anti-oxidant environmental modifi ers, and breast cancer among women on Long Island, New York. Cancer Causes Control 2005;16:1225-1234.
27. Knight JA, Onay UV, Wells S, Li H, Shi EJ, Andrulis IL, et al. Genetic variants of GPX1 and SOD2 and breast cancer risk at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2004;13: 146-149.
28. Silva SN, Cabral MN, Bezerra de Castro G, Pires M, Azevedo AP, Manita I, et al. Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17b1, COMT and MnSOD ): possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed. Oncol Rep 2006;16:781-788.
29. Kostrykina NA, Pechkovskiy EA, Boyarskikh UA, Sushko AG, Voronina EN, Lazarev AF, et al. Associations of polymorphic variant of MnSOD gene with breast cancer in residents of the Altai Region. Bull Exp Biol Med 2009;147:84-87.
30. Bag A and Bag N. Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review. Cancer Epidemiol Biomarkers Prev 2008;17:3298-305.
31. Qiu LX, Yao L, Mao C, Chen B, Zhan P, Yuan H, et al. Lack of association between MnSOD Val16Ala polymorphism and breast cancer risk: a meta-analysis involving 58,448 subjects. Breast Cancer Res Treat 2010;123:543-547.
32. Ma X, Chen C, Xiong H, Fan J, Li Y, Lin H, et al. No association between SOD2 Val16Ala polymorphism and breast cancer susceptibility: a meta-analysis based on 9,710 cases and 11,041 controls. Breast Cancer Res Treat 2010;122:509-514.
33. Wang S, Wang F, Shi X, Dai J, Peng Y, Guo X, et al. Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk-A meta-analysis. Eur J Cancer 2009;45:2874-2881.
34. Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev. 2012;21(2):155-62.
35. Lockett KL, Hall MC, Clark PE, Chuang SC, Robinson B, Lin HY, et al. DNA damage levels in prostate cancer cases and controls. Carcinogenesis. 2006;27(6):1187-93.
36. Polytarchou C, Hatziapostolou M, Papadimitriou E. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affi n regulatory peptide gene. J Biol Chem 2005;280:40428-40435.
37. Liwei L, Chunyu L, Ruifa H. Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis. Urology 2009;74:884-888.
38. Mao C, Qiu LX, Zhan P, Xue K, Ding H, Du FB, et al. MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects. J Cancer Res Clin Oncol 2010;136:975-979.
39. Dasgupta J, Subbaram S, Connor KM, Rodriguez AM, Tirosh O, Beckman JS, et al. Manganese superoxide dismutase protects from TNF-a-induced apoptosis by increasing the steady-state production of H2O2. Antioxid Redox Signal 2006;8: 1295-1305.
40. Stoehlmacher J, Ingles SA, Park DJ, Zhang W, Lenz HJ. The-9Ala/-9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma. Oncol Rep 2002;9:235-238.
41. Sutherland A, Kim DH, Relton C, Ahn YO, Hesketh J. Polymorphisms in the selenoprotein S and 15-kDa selenoprotein genes are associated with altered susceptibility to colorectal cancer. Genes Nutr 2010;5:215-223.
42. M éplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, et al. Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 2010;31: 1074-1079.
43. Levine AJ, Elkhouly E, Diep AT, Lee ER, Frankl H, Haile RW, et al. The MnSOD A16V mitochondrial targeting sequence polymorphism is not associated with increased risk of distal colorectal adenomas: data from a sigmoidoscopybased case control study. Cancer Epidemiol Biomarkers Prev 2002;11:1140-1141.
44. Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, et al. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol 2004;172: 728-732.
45. Terry PD, Umbach DM, Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2005;14:753-754.
46. Cengiz M, Ozaydin A, Ozkilic AC, Dedekarginoglu G. The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients. Int Urol Nephrol 2007;39: 1043-1048.
47. Paz-y-Miño C, Muñoz MJ, López-Cortés A, Cabrera A, Palacios A, Castro B, et al. Frequency of polymorphisms pro198leu in GPX-1 gene and ile58thr in MnSOD gene in the altitude Ecuadorian population with bladder cancer. Oncol Res 2010;18:395-400.
48. Parge HE, Hickey MJ, Johnson MJ, Boissinot M, Hallewell RA, Lepock JR, et al. Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface. Biochemistry 1996;35:4287-4429.
49. Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, et al. Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. Cancer 2008;112: 1037-1042.
50. Mohelnikova-Duchonova B, Marsakova L, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, et al. Superoxide dismutase and nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase polymorphisms and pancreatic cancer risk. Pancreas 2011;40:72-78.
51. Tang H, Dong X, Day RS, Hassan MM, Li D. Antioxidant genes, diabetes and dietary antioxidants in association with risk of pancreatic cancer. Carcinogenesis 2010;31:607-613.
52. Yi JF, Li YM, Liu T, He WT, Li X, Zhou WC, et al. Mn-SOD and CuZn-SOD polymorphisms and interactions with risk factors in gastric cancer. World J Gastroenterol 2010;16: 4738-4746.
53. Tu HK, Pan KF, Zhang Y, Li WQ, Zhang L, Ma JL, et al. Manganese superoxide dismutase polymorphism and risk of gastric lesions, and its effects on chemoprevention in a Chinese population. Cancer Epidemiol Biomarkers Prev 2010;19:1089-1097.
54. Martin RC, Lan Q, Hughes K, Doll MA, Martini BD, Lissowska J, et al. No apparent association between genetic polymorphisms (-102C>T) and (-9T>C) in the human manganese superoxide dismutase gene and gastric cancer. J Surg Res 2005;124:92-97.
55. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 1990;8:583-599.
56. Wang LI, Miller DP, Sai Y, Liu G, Su L, Wain JC, et al. Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst 2001;93:1818-1821.
57. Zejnilovic J, Akev N, Yilmaz H, Isbir T. Association between manganese superoxide dismutase polymorphism and risk of lung cancer. Cancer Genet Cytogenet 2009;189:1-4.
58. Liu G, Zhou W, Park S, Wang LI, Miller DP, Wain JC, et al. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms. Cancer 2004;101:2802-2808.
59. Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, et al. MPO and SOD2 polymorphisms, gender, and the risk of nonsmall cell lung carcinoma. Cancer Lett 2004;214:69-79.
60. Ho JC, Mak JC, Ho SP, Ip MS, Tsang KW, Lam WK, et al. Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong. J Thorac Oncol 2006;1:648-653.
61. Lin P, Hsueh YM, Ko JL, Liang YF, Tsai KJ, et al. Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer 2003;40:123-129.
62. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of nonsmall cell lung cancer in smokers. Carcinogenesis 2008;29: 1164-1169.
63. Gallagher CJ, Ahn K, Knipe AL, Dyer AM, Richie JP Jr, Lazarus P, et al. Association between haplotypes of manganese superoxide dismutase (SOD2), smoking, and lung cancer risk. Free Radic Biol Med 2009;46:20-24.
64. Hernandez-Saavedra D, McCord JM. Association of a new intronic polymorphism of the SOD2 gene (G1677T) with cancer. Cell Biochem Funct 2009;27:223-227.
65. Sun L, König IR, Homann N. Manganese superoxide dismutase (MnSOD) polymorphism, alcohol, cigarette smoking and risk of oesophageal cancer. Alcohol Alcohol 2009;44: 353-357.
66. Murphy SJ, Hughes AE, Patterson CC, Anderson LA, Watson RG, Johnston BT, et al. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 2007;28: 1323-1328.
67. Ribeiro Pinto LF, Teixeira Rossini AM, Albano RM, Felzenszwalb I, de Moura Gallo CV, Nunes RA, et al. Mechanisms of esophageal cancer development in Brazilians. Mutat Res 2003;544:365-373.
68. Cheng YJ, Wang YD, Liu Q, Dong ZM, Wu FP, Yang XR, et al. Association of single nucleotide polymorphism of MnSOD gene with carcinogenesis and development of esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 2009;31:831-835.
69. Han J, Colditz GA, Hunter DJ. Manganese superoxide dismutase polymorphism and risk of skin cancer (United States). Cancer Causes Control 2007;18:79-89.
70. Lan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, et al. Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet 2007;121:161-168.
71. Lightfoot TJ, Skibola CF, Smith AG, Forrest MS, Adamson PJ, Morgan GJ, et al. Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica 2006;91:1222-1227.
72. Tong SY, Lee JM, Song ES, Lee KB, Kim MK, Lee JK, et al. Functional polymorphism in manganese superoxide dismutase and antioxidant status: their interactions on the risk of cervical intraepithelial neoplasia and cervical cancer. Gynecol Oncol 2009;115:272-276.
73. Rajaraman P, Brenner AV, Butler MA, Wang SS, Pfeiffer RM, Ruder AM, et al. Common variation in genes related to innate immunity and risk of adult glioma. Cancer Epidemiol Biomarkers Prev 2009;18:1651-1658.
74. Rajaraman P, Hutchinson A, Rothman N, Black PM, Fine HA, Loeffler JS, et al. Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol 2008;10:709-715.
75. Ezzikouri S, El Feydi AE, Chafik A, AfifiR, El Kihal L, Benazzouz M, et al. Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients. Mutat Res 2008;649:1-6.
76. Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, et al. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol 2004;93: 615-620.
77. Vineis P, Veglia F, Garte S, Malaveille C, Matullo G, Dunning A, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol 2007;18: 1230-1242.
78. Baliga MS, Wang H, Zhuo P, Schwartz JL, Diamond AM. Selenium and GPx-1 overexpression protect mammalian cells against UV-induced DNA damage. Biol Trace Elem Res 2007;115:227-42.
79. Diamond AM, Hu YJ, Mansur DB. Glutathione peroxidase and viral replication: implications for viral evolution and chemoprevention Biofactors 2001;14:205-10.
80. Gouaze V, Andrieu-Abadie N, Cuvillier O, Malagarie-Cazenave S, Frisach MF, Mirault ME, et al. Glutathione peroxidase-1 protects from CD95-induced apoptosis. J Biol Chem 2002;277:42867-42874.
81. Liebman J, Fisher J, Lipshultz C, Kuno R, Kaufman DC. Enhanced glutathione peroxidase expression protects cells from hydroperoxides but not from radiation or doxorubicin. Cancer Res 1995;55:4465-4470.
82. Chu FF, Esworthy RS, Chu PG, Longmate JA, Huycke MM, Wilczynski S, et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 2004;64:962-968.
83. Beevi SS, Rasheed MH, Geetha A. Evidence of oxidative and nitrosative stress in patients with cervical squamous cell carcinoma. Clin Chim Acta 2007;375:119-123.
84. Pawlowicz Z, Zachara BA, Trafikowska U, Maciag A, Marchaluk E, Nowicki A, et al. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. J Trace Elem Electrolytes Health Dis 1991;5:275-277.
85. Zhang X, Yang JJ, Kim YS, Kim KY, Ahn WS, Yang S. An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer. Int J Oncol 2010;36:405-414.
86. Hasegawa Y, Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, et al. Decreased expression of glutathione peroxidase mRNA in thyroid anaplastic carcinoma. Cancer Lett 2002;182:69-74.
87. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, et al. Glutathioneperoxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 2007;67:8043-8050.
88. Reszka E, Gromadzinska J, Jablonska E, Wasowicz W, Jablonowski Z, Sosnowski M, et al. Level of selenoprotein transcripts in peripheral leukocytes of patients with bladder cancer and healthy individuals. Clin Chem Lab Med 2009;47:1125-1132.
89. Moscow JA, Schmidt L, Ingram DT, Gnarra J, Johnson B, Cowan KH, et al. Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis 1994;15:2769-2773.
90. Hardie LJ, Briggs JA, Davidson LA, Allan JM, King RF, Williams GI, Wild CP, et al. The effect of hOGG1 and glutathione peroxidase I genotypes and 3p chromosomal loss on 8-hydroxydeoxyguanosine levels in lung cancer. Carcinogenesis 2000;21:167-172.
91. Hu YJ, Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 2003;63:3347-3351.
92. Ravn-Haren G, Olsen A, Tjønneland A, Dragsted LO, NexøBA, Wallin H, et al. Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis 2006;27:820-825.
93. Cox DG, Hankinson SE, Kraft P, Hunter DJ. No association between GPX1 Pro198Leu and breast cancer risk.Cancer Epidemiol Biomarkers Prev 2004;13(11 Pt 1):1821-1822.
94. Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, et al. No association between glutathione peroxidase Pro198Leu polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005 14: 2459-2461.
95. Cebrian A, Pharoah PD, Ahmed S, Smith PL, Luccarini C, Luben R, et al. Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer Res 2006;66:1225-1233.
96. Hu J, Zhou GW, Wang N, Wang YJ. GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010;124:425-431.
97. Aune D, De Stefani E, Ronco A, Boffetta P, Deneo-Pellegrini H, Acosta G, et al. Fruits, vegetables and the risk of cancer: a multisite case-control study in Uruguay. Asian Pac J Cancer Prev 2009;10:419-428.
98. Ahamed M, Siddiqui MK. Environmental lead toxicity and nutritional factors. Clin Nutr 2007;26:400-408.
99. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 2000;60:6381-6383.
100. Lee CH, Lee KY, Choe KH, Hong YC, Noh SI, Eom SY, et al. Effects of oxidative DNA damage and genetic polymorphism of the glutathione peroxidase 1 (GPX1) and 8-oxoguanine glycosylase 1 (hOGG1) on lung cancer. J Prev Med Public Health 2006;39:130-134.
101. Raaschou-Nielsen O, Sørensen M, Hansen RD, Frederiksen K, Tjønneland A, Overvad K, et al. GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer. Cancer Lett 2007;247:293-300.
102. Rosenberger A, Illig T, Korb K, Klopp N, Zietemann V, Wölke G, et al. Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. BMC Cancer 2008;8:60.
103. Skuladottir H, Autrup H, Autrup J, Tjoenneland A, Overvad K, Ryberg D, et al. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer 2005;48:187-199.
104. Yang P, Bamlet WR, Ebbert JO, Taylor WR, de Andrade M. Glutathione pathway genes and lung cancer risk in young and old populations. Carcinogenesis 2004;25:1935-1944.
105. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett 2001;165:1-10.
106. Wheeler AP, Ridley AJ. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 2004;301: 43-49.
107. Akbaraly NT, Arnaud J, Hininger-Favier I, Gourlet V, Roussel AM, Berr C, et al. Selenium and mortality in the elderly: results from the EVA study. Clin Chem 2005;51: 2117-2123.
108. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998;79:179-192.
109. Clark LC, Hixson LJ, Combs GF, Reid ME, Turnbull BW, Sampliner RE, et al. Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epidemiol Biomark Prev 1993;2:41-46.
110. Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, et al. Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Instit 2004;96: 1669-1675.
111. Hansen R, SaebøM, Skjelbred CF, NexøBA, Hagen PC, Bock G, et al. GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett 2005;229:85-91.
112. Villette S, Kyle JA, Brown KM, Pickard K, Milne JS, Nicol F, et al. A novel single nucleotide polymorphism in the 30 untranslated region of human glutathione peroxidase 4 infl uences lipoxygenase metabolism. Blood Cells Mol Dis 2002;29:174-178.
113. Bermano G, Pagmantidis V, Holloway N, Kadri S, Mowat NA, Shiel RS, et al. Evidence that a polymorphism within the 3-UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. Genes Nutr 2007;2:225-232.
114. Nomura K, Imai H, Koumura T, Arai M, Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase suppresses apoptosis mediated by a mitochondrial death pathway. J Biol Chem 1999;274:22294-29302.
115. Qatatsheh A, Seal CJ, Jowett SL, Welfare MR, Hesketh JE. Patients with ulcerative colitis show an altered frequency distribution of a single nucleotide polymorphism in the gene encoding the phospholipid hydroperoxide glutathione peroxidase. Proc Nutr Soc 2005;64:20A.
116. Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, Shah M, et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 2007;25:3015-3023.
117. Wang JY, Yang IP, Wu DC, Huang SW, Wu JY, Juo SH, et al. Functional glutathione peroxidase 3 polymorphisms associated with increased risk of Taiwanese patients with gastric cancer. Clin Chim Acta 2010;411:1432-1436.
118. Lin JC, Kuo WR, Chiang FY, Hsiao PJ, Lee KW, Wu CW, et al. Glutathione peroxidase 3 gene polymorphisms and risk of differentiated thyroid cancer. Surgery 2009;145: 5085-5089.
119. Wang J, Sun T, Yang M, Lin DX, Tan W, Li KJ, et al. Association of genetic polymorphisms in selenoprotein GPX1 and TXNRD2 with genetic susceptibility of gastric cancer. Zhonghua Yu Fang Yi Xue Za Zhi 2008;42:511-514.
120. Ezzikouri S, El Feydi AE, AfifiR, Benazzouz M, Hassar M, Pineau P, et al. Polymorphisms in antioxidant defence genes and susceptibility to hepatocellular carcinoma in a Moroccan population. Free Radic Res 2010;44:208-216.
121. He C, Qureshi AA, Han J. Polymorphisms in genes involved in oxidative stress and their interactions with lifestyle factors on skin cancer risk. J Dermatol Sci 2010;60: 54-56.
122. Bhatti P, Stewart PA, Hutchinson A, Rothman N, Linet MS, Inskip PD, et al Lead exposure, polymorphisms in genes related to oxidative stress, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev 2009;18:1841-1848.
123. Vogel U, Olsen A, Wallin H, Overvad K, Tjønneland A, NexøBA, et al. No association between GPX Pro198Leu and risk of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:1412-1413.
124. Choi JY, Neuhouser ML, Barnett M, Hudson M, Kristal AR, Thornquist M, et al. Polymorphisms in oxidative stressrelated genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol Biomarkers Prev 2007;16:1115-1120.
125. Erdem O, Eken A, Akay C, Arsova-Sarafinovska Z, Matevska N, Suturkova L, et al. Association of GPX1 polymorphism, GPX activity and prostate cancer risk. Hum Exp Toxicol 2012;31(1):24-31.
126. Goerlitz D, El Daly M, Abdel-Hamid M, Saleh DA, Goldman L, El Kafrawy S, et al. GSTM1, GSTT1 null variants, and GPX1 single nucleotide polymorphism are not associated with bladder cancer risk in Egypt. Cancer Epidemiol Biomarkers Prev 2011;20:1552-1554.
127. Chen J, Cao Q, Qin C, Shao P, Wu Y, Wang M, et al. GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis. J Cancer Res Clin Oncol 2011;137:1553-1561.